Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an emerging growth company, Orchestra BioMed uses current reports on Form 8-K and other filings to describe material agreements, financings, collaborations and governance matters related to its biomedical innovation business.
In these filings, investors can find detailed information about the company’s strategic and financial arrangements that support its flagship programs, Atrioventricular Interval Modulation (AVIM) Therapy and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB). Recent Form 8-K reports describe revenue participation agreements with Ligand Pharmaceuticals tied to future revenues from AVIM Therapy and Virtue SAB, a secured subordinated convertible loan agreement with Medtronic that can convert into a revenue share, and a termination and right of first refusal agreement with Terumo related to Virtue SAB for coronary artery disease.
Filings also cover underwritten public offerings of common stock and pre-funded warrants, private placements with institutional partners, preferred stock issuances, and stock purchase agreements that provide capital for pivotal clinical trials such as the BACKBEAT global study and the Virtue Trial. Additional disclosures include investor presentations furnished under Regulation FD, conference call transcripts, and annual meeting voting results.
On Stock Titan, these OBIO filings are complemented by AI-powered summaries that highlight key terms, counterparties and financial implications, helping readers quickly understand complex documents such as Form 8-Ks, registration statements and related exhibits. Users can review how Orchestra BioMed structures revenue interests, rights of first refusal, convertible instruments and collaboration amendments, and can monitor ongoing reporting about its status as an emerging growth company and its relationships with partners like Medtronic, Terumo and Ligand.
Orchestra BioMed Holdings director Mack John Prosper was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the award shows a per-unit price of $0. The RSUs are scheduled to vest on the one-year anniversary of the grant, subject to the reporting persons continuous service through that date. After this award the reporting person beneficially owns 40,286 shares on a direct basis.
The Form 4 shows the transaction as an acquisition (code A) and was filed by one reporting person. No derivative securities or additional transactions are reported in this filing and no other material details are provided.
Orchestra BioMed director Eric S. Fain was awarded 7,500 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the award shows a transaction price of $0. The RSUs will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through that date.
The Form 4 reports that following the reported acquisition the Reporting Person beneficially owns 7,500 shares directly and 58,449 shares indirectly through the Fain Living Trust. The filing discloses the RSU grant as the non-derivative acquisition reported on the form.
Orchestra BioMed Holdings, Inc. (OBIO) filed a Form 4 reporting that director Chris Cleary was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the grant is recorded with a price of $0 in the filing. The RSUs are scheduled to vest on the one-year anniversary of the grant date, subject to the reporting persons continuous service through that date.
The transaction is shown as an acquisition and, after the award, Mr. Cleary beneficially owns 37,577 shares on a direct basis. The Form 4 was filed by one reporting person and was signed by an attorney-in-fact on 08/08/2025.
Orchestra BioMed Holdings reported that Director and CEO David P. Hochman was awarded 100,000 restricted stock units (RSUs) on 08/07/2025, each representing a contingent right to one share of common stock. After the award, Mr. Hochman's reported direct beneficial ownership is 645,460 shares; indirect holdings include 449,331 shares held by the DPH 2008 Trust and smaller trust holdings of 2,000, 2,000, 2,000 and 3,140 shares. The RSUs vest over three years in three tranches: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months, subject to continuous service. The filing identifies Mr. Hochman as Chief Executive Officer and Chairperson.
Orchestra BioMed director David Pacitti was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the RSUs vest on the one-year anniversary of the grant, subject to the reporting person's continuous service through that date.
Following the award, the reporting person beneficially owns 44,968 shares of common stock in a direct ownership form. The RSUs carry no stated cash price and will convert to shares upon vesting.
Joshua Aiello, Principal Accounting Officer at Orchestra BioMed Holdings, Inc. (OBIO), reported an award of 15,000 restricted stock units (RSUs) on August 7, 2025. Each RSU represents a contingent right to one share of common stock and the grant lists a $0 per-share price. The RSUs vest in three tranches over three years: 33.33% vest 24 months after the grant date, 33.33% vest 30 months after the grant date, and 33.34% vest 36 months after the grant date, subject to continuous service. The Form 4 shows 19,329 shares as beneficially owned following the reported transaction and is signed by an attorney-in-fact on August 8, 2025.
RTW Investments, LP and affiliated funds ("RTW") filed Amendment No. 5 to Schedule 13D on Orchestra BioMed Holdings, Inc. (OBIO) dated 08 Aug 2025. The amendment reflects RTW’s 04 Aug 2025 purchase of 3,636,363 pre-funded warrants at $2.7499 each (total $9.999 million) in the company’s August 2025 public offering. The warrants carry a de-minimis exercise price of $0.0001 but are subject to a 9.99 % ownership cap (adjustable up to 19.99 % after 61 days), so the underlying shares are not presently deemed beneficially owned.
After the transaction RTW reports 8,306,063 common shares, equating to 15.4 % of OBIO’s 53,952,798 outstanding shares. Break-down: RTW Master Fund 4.395 M (8.1 %), RTW Innovation Master Fund 3.053 M (5.7 %), RTW Biotech Fund 0.858 M (1.6 %). Dr. Roderick Wong, Managing Partner, is the controlling individual and is deemed to share voting and dispositive power over all reported shares.
Key investor takeaways: RTW remains OBIO’s largest known shareholder, injected ~$10 M fresh capital, and holds additional warrant optionality that could increase its stake and dilute existing holders once exercise restrictions lapse.
On 08/04/2025, RTW Investments, LP—together with Managing Partner Dr. Roderick Wong—filed a Form 4 disclosing the purchase of 3,636,363 pre-funded warrants in Orchestra BioMed Holdings (OBIO). The warrants were acquired at $2.7499 per warrant (Transaction Code “P”) and carry a nominal exercise price of $0.0001 per share. Each warrant is immediately exercisable into one common share, but exercise is limited so total beneficial ownership does not exceed 9.99 % of OBIO’s outstanding stock.
The filing confirms RTW and Dr. Wong as >10 % shareholders and directors. Post-transaction, they hold 3.64 million derivative securities that, if fully exercised, could add an equivalent number of common shares to OBIO’s float, creating potential dilution. The warrants have no expiration date, giving the insiders flexibility on timing.
Perceptive Advisors LLC and affiliated entities, already a >10 % shareholder of Orchestra BioMed Holdings (OBIO), filed Form 4 disclosing additional purchases on 1 Aug 2025.
- Acquired 700,000 common shares at $2.75 per share through the issuer’s registered public offering (transaction code “P”).
- Acquired 1,500,000 pre-funded warrants (exercise price $0.0001; purchase price $2.7499) that are immediately exercisable, subject to a beneficial-ownership cap.
- Following the transactions, indirect beneficial ownership stands at 5,292,556 common shares and 1,500,000 warrants.
- Filers listed are Perceptive Advisors LLC (investment manager), Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman (managing member). No dispositions were reported.
The filing signals continued capital commitment by a significant insider during the public offering.
Orchestra BioMed Holdings (OBIO) – Form 4 insider activity
On 08/04/2025, Chief Executive Officer & Chairperson David P. Hochman purchased 20,000 common shares in the company’s underwritten public offering at $2.75 per share, investing $55,000. The shares were bought indirectly through the DPH 2008 Trust, raising that trust’s position to 349,331 shares.
Following the acquisition, Hochman’s total beneficial ownership stands at 903,931 shares, consisting of 545,460 shares held directly and 358,471 shares held through five family trusts (DPH 2008, Solomon Ascher 2019, Hannah 2019, Judah Herman 2019, NSH 2008). No shares were sold and no derivative securities were reported in the filing.
The transaction increases the CEO’s economic exposure and signals participation in the recent capital raise, but the filing contains no financial results, guidance, or other operational disclosures.